BRPI0414017B8 - pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços. - Google Patents

pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.

Info

Publication number
BRPI0414017B8
BRPI0414017B8 BRPI0414017A BRPI0414017A BRPI0414017B8 BR PI0414017 B8 BRPI0414017 B8 BR PI0414017B8 BR PI0414017 A BRPI0414017 A BR PI0414017A BR PI0414017 A BRPI0414017 A BR PI0414017A BR PI0414017 B8 BRPI0414017 B8 BR PI0414017B8
Authority
BR
Brazil
Prior art keywords
prodrugs
arm polymeric
polymeric prodrug
water
soluble
Prior art date
Application number
BRPI0414017A
Other languages
English (en)
Inventor
D Bentley Michael
X Viegas Tacey
Zhao Xuan
Ren Zhongxu
Original Assignee
Nektar Therapeutics Al Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics Al Corp filed Critical Nektar Therapeutics Al Corp
Publication of BRPI0414017A publication Critical patent/BRPI0414017A/pt
Publication of BRPI0414017A8 publication Critical patent/BRPI0414017A8/pt
Publication of BRPI0414017B1 publication Critical patent/BRPI0414017B1/pt
Publication of BRPI0414017B8 publication Critical patent/BRPI0414017B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyethers (AREA)

Abstract

pró-fármacos poliméricos de múltiplos braços apresentados neste documento são pró-fármacos solúveis em água. os pró-fármacos da invenção compreendem um polímero solúvel em água que possui um ou mais braços, dos quais pelo menos três estão covalentemente ligados a um agente ativo, por exemplo, uma molécula pequena. os conjugados da invenção proporcionam um equilíbrio otimizado entre a dimensão e a estrutura do polímero para a obtenção de uma incorporação aprimorada do fármaco, uma vez que os conjugados da invenção possuem três ou mais agentes ativos ligados de forma passível de liberação a um polímero de múltiplos braços solúvel em água. os pró-fármacos da invenção têm eficácia terapêutica e demonstram propriedades aprimoradas in vivo quando comparados a um fármaco primário que não foi modificado.
BRPI0414017A 2003-09-17 2004-09-17 pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços. BRPI0414017B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50367303P 2003-09-17 2003-09-17
US60/503,673 2003-09-17
US58430804P 2004-06-30 2004-06-30
US60/584,308 2004-06-30
PCT/US2004/030720 WO2005028539A2 (en) 2003-09-17 2004-09-17 Multi-arm polymer prodrugs

Publications (4)

Publication Number Publication Date
BRPI0414017A BRPI0414017A (pt) 2006-09-05
BRPI0414017A8 BRPI0414017A8 (pt) 2018-04-24
BRPI0414017B1 BRPI0414017B1 (pt) 2019-04-09
BRPI0414017B8 true BRPI0414017B8 (pt) 2021-05-25

Family

ID=34381082

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414017A BRPI0414017B8 (pt) 2003-09-17 2004-09-17 pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.

Country Status (18)

Country Link
US (4) US7744861B2 (pt)
EP (2) EP1675622B1 (pt)
JP (4) JP5632119B2 (pt)
KR (2) KR101200729B1 (pt)
CN (2) CN1852740B (pt)
AU (2) AU2004274489B2 (pt)
BR (1) BRPI0414017B8 (pt)
CA (1) CA2537336C (pt)
CY (1) CY1119303T1 (pt)
DK (1) DK1675622T3 (pt)
ES (1) ES2629696T3 (pt)
HR (1) HRP20171094T1 (pt)
HU (1) HUE036290T2 (pt)
LT (1) LT1675622T (pt)
PL (1) PL1675622T3 (pt)
PT (1) PT1675622T (pt)
SI (1) SI1675622T1 (pt)
WO (1) WO2005028539A2 (pt)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
US20060014697A1 (en) * 2001-08-22 2006-01-19 Travis Mickle Pharmaceutical compositions for prevention of overdose or abuse
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
US8394365B2 (en) 2003-09-17 2013-03-12 Nektar Therapeutics Multi-arm polymer prodrugs
ES2629696T3 (es) * 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
KR101312417B1 (ko) * 2005-05-11 2013-09-27 니폰 가야꾸 가부시끼가이샤 시티딘계 대사길항제의 고분자 유도체
CA2653541C (en) 2005-06-06 2014-12-23 The University Of British Columbia Polymer-based serum albumin substitute
EP1898955A2 (en) 2005-06-17 2008-03-19 Nektar Therapeutics AL, Corporation Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
JP5192384B2 (ja) 2005-09-22 2013-05-08 メディバス エルエルシー ビス−（α−アミノ）−ジオール−ジエステル含有ポリ（エステルアミド）およびポリ（エステルウレタン）組成物および使用の方法
CA2623239C (en) * 2005-09-22 2016-07-12 Medivas, Llc Solid polymer delivery compositions and methods for use thereof
JP2009524584A (ja) * 2005-12-07 2009-07-02 メディバス エルエルシー ポリマー−生物製剤送達組成物を構築するための方法
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
TWI426905B (zh) * 2006-02-09 2014-02-21 安龍製藥公司 用於乳癌、大腸直腸癌、胰臟癌、卵巢癌及肺癌之治療的７-乙基-１０羥喜樹鹼之多臂聚合性共軛物
DK1988910T3 (en) 2006-02-28 2018-01-22 Kodiak Sciences Inc ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE-CONTAINING POLYMER CONJUGATES AND PREPARATION thereof
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
US20070282011A1 (en) * 2006-05-09 2007-12-06 Medivas, Llc Biodegradable water soluble polymers
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
CN101583380B (zh) 2006-11-30 2013-07-10 尼克塔治疗公司 用于制备聚合物轭合物的方法
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008098178A2 (en) * 2007-02-09 2008-08-14 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
JP5428017B2 (ja) * 2007-03-23 2014-02-26 国立大学法人 熊本大学 ワクチン剤
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9241998B2 (en) * 2007-05-21 2016-01-26 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oncolytic RSV activity
US20090029937A1 (en) * 2007-07-24 2009-01-29 Cornell University Biodegradable cationic polymer gene transfer compositions and methods of use
WO2009025669A1 (en) * 2007-08-20 2009-02-26 Enzon Pharmaceuticals, Inc. Polymeric linkers containing pyridyl disulfide moieties
WO2009026543A2 (en) * 2007-08-23 2009-02-26 Medivas, Llc Cationic alpha-amino acid-containing biodegradable polymer gene transfer compositions
US8088884B2 (en) * 2007-09-27 2012-01-03 Serina Therapeutics, Inc. Multi-armed forms of activated polyoxazoline and methods of synthesis thereof
EP2630966B1 (en) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Vaccine nanotechnology
WO2009058387A2 (en) 2007-11-02 2009-05-07 Nektar Therapeutics Al, Corporation Oligomer-nitroimidazole anti-infective conjugates
WO2009121564A1 (en) * 2008-03-31 2009-10-08 Freie Universität Berlin Drug conjugates with polyglycerols
EP2216049A1 (en) * 2009-02-06 2010-08-11 Freie Universität Berlin Drug conjugates with polyglycerols
US8357385B2 (en) * 2008-04-07 2013-01-22 Interface Biologics Inc. Combination therapy for the treatment of bacterial infections
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
CA2733686A1 (en) * 2008-08-13 2010-02-18 Medivas, Llc Aabb-poly(depsipeptide) biodegradable polymers and methods of use
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
US20110165112A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of c-peptides
EP2341942A1 (en) 2008-09-19 2011-07-13 Nektar Therapeutics Polymer conjugates of therapeutic peptides
HUE047352T2 (hu) * 2008-09-23 2020-04-28 Nektar Therapeutics Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal)
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
CA2738807A1 (en) * 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
KR20100083632A (ko) * 2009-01-14 2010-07-22 울산대학교 산학협력단 표적 단백질 분해효소 감응형 항암제 전구체
CA2760771A1 (en) * 2009-05-04 2010-11-11 Intezyne Technologies, Incorporated Polymer micelles containing sn-38 for the treatment of cancer
US20120171201A1 (en) * 2009-07-22 2012-07-05 Enzon Pharmaceuticals, Inc. Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
US8722732B2 (en) 2009-09-29 2014-05-13 Nektar Therapeutics Oligomer-calcimimetic conjugates and related compounds
ME03396B (me) * 2009-11-18 2020-01-20 Nektar Therapeutics Oblici kisele soli konjugata polimer-lek
US8765432B2 (en) 2009-12-18 2014-07-01 Oligasis, Llc Targeted drug phosphorylcholine polymer conjugates
CN102906157B (zh) 2010-03-01 2016-08-24 不列颠哥伦比亚大学 衍生的超支化聚丙三醇
CA2798518A1 (en) 2010-05-17 2011-11-24 Cebix, Inc. Pegylated c-peptide
CN102339813A (zh) 2010-07-14 2012-02-01 中国科学院微电子研究所 半导体结构及其制造方法
US20120016390A1 (en) * 2010-07-16 2012-01-19 Knc Ner Acquisition Sub, Inc. Bioadhesive compounds and methods of synthesis and use
EP2598171A2 (en) * 2010-07-28 2013-06-05 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
WO2012083197A1 (en) 2010-12-17 2012-06-21 Nektar Therapeutics Water-soluble polymer conjugates of topotecan
WO2012088282A1 (en) * 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
WO2012088529A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-sunitinib conjugates
WO2012088522A1 (en) 2010-12-23 2012-06-28 Nektar Therapeutics Polymer-des-ethyl sunitinib conjugates
WO2012162175A1 (en) 2011-05-20 2012-11-29 Howard University Emetine derivatives, prodrugs containing same, and methods of treating conditions using same
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
WO2012177825A1 (en) 2011-06-21 2012-12-27 Bvw Holding Ag Medical device comprising boswellic acid
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9963549B2 (en) 2011-06-23 2018-05-08 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
AU2012296950B2 (en) 2011-08-12 2016-09-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
WO2013024047A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
CN102935066B (zh) * 2011-08-16 2014-09-17 齐鲁制药有限公司 一种伊立替康脂质体制剂及其制备方法
US20140378404A1 (en) 2011-10-25 2014-12-25 Nektar Therapeutics Treatment of Patients Suffering from Cancer
US8383093B1 (en) * 2011-11-01 2013-02-26 Serina Therapeutics, Inc. Subcutaneous delivery of poly(oxazoline) conjugates
CN103083680B (zh) 2011-11-07 2014-12-24 北京键凯科技有限公司 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物
RU2493848C1 (ru) * 2012-06-14 2013-09-27 Геннадий Петрович Власов Биодеградируемый полимерный носитель для доставки противоопухолевого лекарственного средства (варианты)
JP6300460B2 (ja) * 2012-07-20 2018-03-28 キヤノン株式会社 化合物、および前記化合物を有する光音響イメージング用造影剤
CN104813167B (zh) * 2012-11-28 2019-04-09 尼克塔治疗公司 用于评估和预测用一种长效拓扑异构酶i抑制剂进行乳腺癌治疗的疗效的方法
US9863949B2 (en) 2013-05-31 2018-01-09 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
JP6463361B2 (ja) 2013-09-08 2019-01-30 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
JP5721806B2 (ja) * 2013-10-04 2015-05-20 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 副作用のない抗癌剤
DK3052101T3 (da) * 2013-10-04 2019-12-16 Prolynx Llc Konjugater af sn-38 med langsom frigivelse
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3094331B1 (en) 2014-01-14 2017-12-27 Nektar Therapeutics Combination-based treatment method
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
JP6542799B2 (ja) * 2014-12-04 2019-07-10 Ｄｅｌｔａ−Ｆｌｙ Ｐｈａｒｍａ株式会社 新規ｐｅｇ誘導体
EP3233067B1 (en) 2014-12-18 2019-11-06 DSM IP Assets B.V. Drug delivery system for delivery of acid sensitive drugs
KR102799807B1 (ko) 2015-12-30 2025-04-24 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
CN107375288B (zh) * 2016-05-16 2019-08-23 博瑞生物医药（苏州）股份有限公司 多臂的聚合靶向抗癌偶联物
EP3496760B1 (en) * 2016-08-09 2022-02-09 The University of Liverpool Ophthalmic compositions
KR102619747B1 (ko) 2017-01-10 2023-12-29 넥타르 테라퓨틱스 Tlr 효현제 화합물의 다중-아암 중합체 컨쥬게이트 및 관련 면역 요법적 치료 방법
JP2020105072A (ja) * 2017-03-24 2020-07-09 協和キリン株式会社 ポリエチレングリコール誘導体
CN108727584B (zh) * 2017-04-21 2021-01-05 博瑞生物医药（苏州）股份有限公司 抗癌偶联物
EP3613792B1 (en) * 2017-04-21 2021-02-24 Bright Gene Bio-Medical Technology Co., Ltd. Multi-arm targeted anti-cancer conjugate
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
CN109776787B (zh) * 2017-11-14 2021-08-03 博瑞生物医药（苏州）股份有限公司 多臂靶向偶联物
CN109771658B (zh) * 2017-11-14 2021-12-10 博瑞生物医药（苏州）股份有限公司 靶向多臂偶联物
CN109776788B (zh) * 2017-11-14 2021-07-30 博瑞生物医药（苏州）股份有限公司 叶酸受体靶向多臂偶联物
WO2019096096A1 (zh) * 2017-11-14 2019-05-23 博瑞生物医药（苏州）股份有限公司 多臂靶向偶联物
US20200347359A1 (en) * 2018-01-08 2020-11-05 The Regents Of The University Of Colorado, A Body Corporate 3D in vitro Models of Lung Tissue
MX2020007306A (es) 2018-01-12 2020-09-25 Prolynx Llc Tratamiento sinergico de cancer.
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
JP7546552B2 (ja) 2018-09-17 2024-09-06 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア ポリマーベースの高分子プロドラッグ
WO2020081684A1 (en) * 2018-10-16 2020-04-23 Rensselaer Polytechnic Institute Synthesis and processing of poly(pro-drug) materials for extended drug release and uses thereof
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
CN111603567B (zh) 2019-02-22 2024-12-27 赣江新区博瑞创新医药有限公司 Cd44靶向多臂偶联物
EP3958907A1 (en) * 2019-08-28 2022-03-02 Boston Scientific Scimed Inc. Multi-armed polyoxazolines and compositions, systems and methods pertaining to the same
CN114269811B (zh) * 2019-08-28 2023-08-08 波士顿科学国际有限公司 包含自由基可聚合单体的多臂聚合物
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL291786A (en) 2019-11-04 2022-06-01 Synthorx Inc Interleukin 10 conjugates and their use
US12577398B2 (en) 2019-11-12 2026-03-17 Dsm Ip Assets B.V. Polyesteramide copolymers possessing high glass transition temperatures
PL3928835T3 (pl) * 2020-05-14 2024-02-12 Delta-Fly Pharma, Inc. Rozpuszczalna w wodzie polimerowa pochodna wenetoklaksu
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy
WO2026055280A1 (en) 2024-09-04 2026-03-12 Sanofi Interleukin 2 (il-2) and cd123 nk cell engager combination therapy

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993024476A1 (en) * 1992-06-04 1993-12-09 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
TW438775B (en) * 1995-04-07 2001-06-07 Pharmacia & Upjohn Co Llc Novel intermediates and process for the manufacture of camptothecin derivatives (CPT-11) and related compounds
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
CZ391097A3 (cs) 1995-06-07 1998-07-15 Ortho Pharmaceutical Corporation Látky a peptidy vážící se na erythropoietinový receptor
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
DE69735057T2 (de) 1996-03-12 2006-08-31 PG-TXL Co., L.P., Houston Wasserlösliche paclitaxel-prodrogen
FR2746308B1 (fr) 1996-03-22 1998-04-30 Oreal Compositions de teinture des fibres keratiniques contenant des imidazolo-azoles ; leur utilisation en teinture comme coupleurs ; procede de teinture
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6011042A (en) 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6111107A (en) 1997-11-20 2000-08-29 Enzon, Inc. High yield method for stereoselective acylation of tertiary alcohols
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
DK1411075T3 (da) 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
US6153655A (en) 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
DE29812626U1 (de) 1998-07-15 1998-11-12 SCM Microsystems GmbH, 85276 Pfaffenhofen Kartenleser für Chipkarten
EP1176985A2 (en) 1999-04-28 2002-02-06 Vectramed, Inc. Enzymatically activated polymeric drug conjugates
WO2000066125A1 (en) 1999-04-29 2000-11-09 Aventis Pharma S.A. Method for treating cancer using camptothecin derivatives and 5-fluorouracil
US6541508B2 (en) 1999-09-13 2003-04-01 Nobex Corporation Taxane prodrugs
AU781839B2 (en) 1999-12-22 2005-06-16 Nektar Therapeutics Sterically hindered derivatives of water soluble polymers
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
WO2001062827A2 (en) * 2000-02-22 2001-08-30 Shearwater Corporation N-maleimidyl polymer derivatives
AU2001257577A1 (en) * 2000-02-28 2001-09-03 Shearwater Corporation Water-soluble polymer conjugates of artelinic acid
US6756037B2 (en) 2000-03-31 2004-06-29 Enzon, Inc. Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6629995B1 (en) 2000-03-31 2003-10-07 Super Gen, Inc. Camptothecin conjugates
US6777387B2 (en) 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
EP1301810B1 (en) 2000-07-21 2008-09-10 Services Petroliers Schlumberger Nuclear magnetic resonance methods for extracting information about a fluid in a rock
EP1355671A2 (en) * 2000-11-30 2003-10-29 Nektar Therapeutics Al, Corporation Water-soluble polymer conjugates of triazine derivatives
AU2002303164A1 (en) * 2001-03-23 2002-10-08 Protarga, Inc. Fatty amine drug conjugates
US20030108556A1 (en) * 2001-06-08 2003-06-12 Mekalanos John J. Therapeutic uses of polyvalent compositions in infectious diseases
WO2003033525A1 (en) 2001-10-12 2003-04-24 Debio Recherche Pharmacuetique S.A. Amino-substituted camptothecin polymer derivatives and use of the same for the manufacture of a medicament
WO2003037384A2 (en) * 2001-10-29 2003-05-08 Nektar Therapeutics Al, Corporation Polymer conjugates of protein kinase c inhibitors
KR20050042013A (ko) * 2001-10-30 2005-05-04 넥타르 테라퓨틱스 에이엘, 코포레이션 레티노산의 수용성 중합체 콘쥬게이트
US6608076B1 (en) 2002-05-16 2003-08-19 Enzon, Inc. Camptothecin derivatives and polymeric conjugates thereof
CN1668293A (zh) * 2002-06-06 2005-09-14 华盛顿大学 使用青蒿素样化合物预防或延缓癌症显现的方法
US7122189B2 (en) 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
BRPI0314042B8 (pt) * 2002-09-06 2021-05-25 Calando Pharmaceuticals Inc polímeros à base de ciclodextrina para o fornecimento de agentes terapêuticos ligados a eles por covalência
ES2629696T3 (es) 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo

Also Published As

Publication number Publication date
HUE036290T2 (hu) 2018-06-28
BRPI0414017A (pt) 2006-09-05
CN1852740B (zh) 2011-05-11
US20050112088A1 (en) 2005-05-26
US20100152414A1 (en) 2010-06-17
EP1675622B1 (en) 2017-06-14
AU2011202402B2 (en) 2013-12-12
DK1675622T3 (en) 2017-09-18
US8318145B2 (en) 2012-11-27
PT1675622T (pt) 2017-09-19
LT1675622T (lt) 2017-09-11
US7744861B2 (en) 2010-06-29
CY1119303T1 (el) 2018-02-14
JP2014196321A (ja) 2014-10-16
JP2017119706A (ja) 2017-07-06
KR20120073370A (ko) 2012-07-04
WO2005028539A2 (en) 2005-03-31
BRPI0414017B1 (pt) 2019-04-09
JP6166014B2 (ja) 2017-07-19
EP2626083A1 (en) 2013-08-14
JP5632119B2 (ja) 2014-11-26
JP2011213727A (ja) 2011-10-27
AU2011202402A1 (en) 2011-06-09
JP2007505928A (ja) 2007-03-15
KR101200729B1 (ko) 2012-11-13
US20100190933A1 (en) 2010-07-29
EP1675622A2 (en) 2006-07-05
ES2629696T3 (es) 2017-08-14
WO2005028539A3 (en) 2005-11-24
US20080194612A1 (en) 2008-08-14
CN102172405B (zh) 2014-11-12
AU2004274489A1 (en) 2005-03-31
KR20060090705A (ko) 2006-08-14
CN102172405A (zh) 2011-09-07
CN1852740A (zh) 2006-10-25
HRP20171094T1 (hr) 2017-10-06
US8263062B2 (en) 2012-09-11
CA2537336A1 (en) 2005-03-31
BRPI0414017A8 (pt) 2018-04-24
AU2004274489B2 (en) 2011-06-09
PL1675622T3 (pl) 2017-11-30
CA2537336C (en) 2013-02-26
SI1675622T1 (sl) 2017-09-29

Similar Documents

Publication Publication Date Title
BRPI0414017B8 (pt) pró-fármaco polimérico de múltiplos braços, composição farmacêutica e método para a preparação de um pró-fármaco polimérico de múltiplos braços.
WO2011079279A3 (en) Nanoconjugates and nanoconjugate formulations
BRPI0911442A2 (pt) conjugados potentes e ligantes hidrofílicos
WO2006039336A3 (en) Conveniently implantable sustained release drug compositions
WO2004093795A3 (en) Compositions for delivery of drug combinations
BR0113663A (pt) Composições de pelìcula de pectina
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
DE60144281D1 (de) Neues kationisches lipopolymer als biokompatible gentransfer-mittel
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2007100905A3 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2010039496A3 (en) Nanocarriers for drug delivery
BR0212475A (pt) Composições farmacêuticas
CY1111389T1 (el) Φαρμακευτικες ενωσεις που περιεχουν ιματινιμπη και ενα επιβραδυντικο εκλυσης
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
WO2006110776A3 (en) Polyethylene glycol cojugates of antimicrobial agents
CY1115891T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
CN105142620A (zh) 用于受控释放抗生物膜剂的纳米颗粒
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
BRPI0615860B8 (pt) composição farmacêutica de liberação prolongada monolítica sólida
WO2008085556A3 (en) Surfactant-free nanoparticles for drug delivery
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
WO2003028696A8 (en) Compositions for delivery of drug combinations
ATE426635T1 (de) Arzneimittelverabreichung
WO2005072343A3 (en) Aqueous pharmaceutical compositions 2,6-diisopropylphenol (propofol) and their use

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C08L 71/02 (2006.01), A61K 47/58 (2017.01), A61K 4

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/09/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: NEKTAR THERAPEUTICS (US)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2792 DE 09-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.